Company news
Zentalis Pharmaceuticals, Inc. news in 2026
Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
November 9, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
November 3, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 2, 2026
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
October 23, 2026
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
October 18, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
August 18, 2026
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 17, 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
August 13, 2026
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
August 13, 2026
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
July 17, 2026
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
May 27, 2026
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
May 21, 2026
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
May 12, 2026
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
May 5, 2026
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
May 4, 2026
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
April 20, 2026
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
April 17, 2026
Zentalis Pharmaceuticals Announces 400mg QD 5: 2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
April 8, 2026
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
March 26, 2026
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 17, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
February 3, 2026
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
January 6, 2026
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 25 slides · Nov 9, 2026
- Investor Presentation (August 2026)
Investor deck · 29 slides · August 2026
- Investor Presentation (May 2026)
Investor deck · 29 slides · May 12, 2026
- Investor Presentation (April 2026)
Investor deck · 39 slides · Apr 9, 2026
- Investor Presentation (January 2026)
Investor deck · 40 slides · Jan 9, 2026